button bars forest bayes pooled summary circles
 
CRR

mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population

versus gemcitabine plus platin
atezolizumab alone vs. gemcitabine plus platin 1 -
durvalumab alone vs. gemcitabine plus platin 1 -
pembrolizumab plus SoC vs. gemcitabine plus platin 1 -
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable+96%
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -

mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive

versus gemcitabine plus platin
durvalumab alone vs. gemcitabine plus platin 1 -

mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 1 -
pembrolizumab alone vs. Standard of Care (SoC) 1 -

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 2 -
pembrolizumab alone vs. Standard of Care (SoC) 1 -

mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population

versus BSC
avelumab alone vs. BSC 1 -

mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive

versus BSC
avelumab alone vs. BSC 1 -

MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population

versus no additional treatment
atezolizumab alone vs. no additional treatment 1 -
versus placebo
nivolumab alone vs. placebo 1 -

MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive

versus placebo
nivolumab alone vs. placebo 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons